Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Oncogenes drive cancer, but targeted therapies often face resistance.
• Small molecule inhibitors targeting oncogenes have shown limited success in curing patients.
• Tumor-infiltrating T cells (T cells) offer a potential alternative for targeting cancer drivers.

Purpose of the Study:

• To investigate the efficacy of T cell immunotherapy targeting the BRAFV600E mutation in metastatic melanoma.
• To explore the potential of adoptive T cell transfer for treating cancers with specific oncogenic drivers.

Main Methods:

• Described a patient with metastatic acral melanoma treated with tumor-infiltrating T cells.
• Utilized T cells engineered to express a T cell receptor (TCR) targeting the BRAFV600E mutation.
• Demonstrated recognition of a BRAFV600E-specific epitope by the engineered T cells.

Main Results:

• The patient achieved a complete tumor response following T cell infusion.
• Engineered T cells successfully recognized an epitope spanning the BRAFV600E mutation.
• This indicates BRAFV600E can be a target for T cell-mediated therapy.

Conclusions:

• Adoptive transfer of anti-BRAFV600E T cells is a potential therapeutic strategy.
• Targeting oncogenic drivers like BRAFV600E with T cell immunotherapy is a promising paradigm.
• This approach may overcome resistance seen with conventional oncogene-targeted therapies.